Abstract: Successful application of an engineered protein as therapeutics or in other industries would require the protein to have good expression level, good biophysical properties and often desired affinity to its target. The present invention provides a method of screening large numbers of protein candidates (PCs) in all three aspects simultaneously. PCs are fused to a protein anchor, which is captured by the target/antigen. The captured PCs are evaluated for their expression levels, biophysical properties and affinities using conventional methods.

Abstract: The subject invention provides, for example, a novel approach to specifically induce intranasal and/or oral mucosal as well as humoral antibody response by administrating a mucosal delivery pentabody complex (MDPC). The MDPC is a complex formed by mixing a target antigen and a mucosal delivery pentabody (MDP) that has a strong affinity to the target antigen. The MDP is a fusion protein of a single domain antibody (sdAb; which binds to the target antigen specifically) to a pentamerization domain (which can include the B-subunit of an AB5 toxin family, including the B subunit of cholera toxin (CT) or heat-labile toxin (LT)). The pentamerization domain can self-assemble into a pentamer, through which a pentameric single domain antibody, or a pentabody, is formed.

Abstract: The invention relates to antibodies specific to serum albumins. More specifically, the invention relates to camelid single domain antibodies and pentabodies binding to serum albumins of various species with various affinities.

Abstract: A novel single domain antibody AFAI and fragments thereof which has specific affinity for binding to carcinoma, and especially lung carcinoma. This antibody, and portions thereof, can be used, inter alia in the diagnosis and treatment of carcinoma.

Abstract: There is provided a method of forming a multimeric complex having affinity for a target. The method comprises: obtaining a plurality of self-assembly molecules, said self-assembly molecules including complementary self-assembly units such as verotoxin subunit B, each of which is operatively connected to an interaction domain such as a single domain antibody specific for the target; and combining said self-assembly molecules such that at least three said self-assembly units simultaneously bind to one another so as to permit the single domain antibodies to bind the target.

Abstract: There is disclosed herein subunits and multimers of subunits suitable for use in inducing the transport of one or more cargo substances into a cell and in some instances across a cell. The subunits may have a targeting domain such a antibody or antibody fragment, a multimerization domain, such as a verotoxin B-subunit mutant scaffold, and a cargo molecule such as a drug or imaging agent, which may be directly linked to the subunit or may be packaged in a liposome, nanoparticle, or the like. In some instances the targeting domain may have affinity for a blood-brain barrier antigen and may be capable of inducing cell mediated transcytosis to facilitate delivery of the cargo molecule across the blood-brain barrier. In some instances the targeting region may have affinity for a cancer antigen and may be capable of inducing cell-mediated endocytosis.

Abstract: Disclosed herein are lung cancer specific binding agents, as well as related amino acid and nucleic acid sequences. Methods of using such agents in the diagnosis and treatment of treat lung cancer are also disclosed. In an embodiment of the invention there is provided an antibody or fragment thereof comprising the sequence Ser Gly Asn Gly Gly Thr in the region corresponding to the CDR 2.

Abstract: A novel single domain antibody AFAI and fragments thereof which has specific affinity for binding to carcinoma, and especially lung carcinoma. This antibody, and portions thereof, can be used, inter alia in the diagnosis and treatment of carcinoma.

Abstract: There is provided a method of forming a multimeric complex having affinity for a target. The method comprises: obtaining a plurality of self-assembly molecules, said self-assembly molecules including complementary self-assembly units such as verotoxin subunit B, each of which is operatively connected to an interaction domain such as a single domain antibody specific for the target; and combining said self-assembly molecules such that at least three said self-assembly units simultaneously bind to one another so as to permit the single domain antibodies to bind the target.